More than 20 fully/heavily outsourced sponsors contributed to this whitepaper which explores the implications of ICH E6(R3) on outsourced sponsors and provides valuable insights to ensure a smooth transition to the new guidance.
Learn why every emerging biotech needs a validated oversight system for compliance.